Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | ATR | Q13535 | 4/20 | 0.53 |
| ▸ | MAP4K3 | Q8IVH8 | 4/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 7/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.49 |
| ▸ | GRK2 | P25098 | 2/20 | 0.45 |
| ▸ | GRK5 | P34947 | 2/20 | 0.45 |
| ▸ | KHK | P50053 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045605 | 0.90 | EGFR (0.74) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL4042032 | 0.89 | EGFR (0.62) | EGFRATRMAP4K3FGFR1FGFR2 | |
| SCHEMBL4045729 | 0.86 | EGFR (0.60) | EGFRATRMAP4K3FGFR1FGFR2 | |
| SCHEMBL4038019 | 0.85 | EGFR (0.80) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL4052591 | 0.83 | EGFR (0.64) | EGFRATRMAP4K3FGFR1FGFR2 | |
| SCHEMBL4044744 | 0.83 | EGFR (0.56) | EGFRMAP4K3FGFR1FGFR2FGFR3 | |
| SCHEMBL4044782 | 0.79 | EGFR (0.61) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL4045589 | 0.79 | EGFR (0.56) | EGFRATRMAP4K3FGFR1FGFR2 | |
| SCHEMBL4044231 | 0.79 | EGFR (0.78) | EGFRATRFGFR1FGFR2FGFR3 | |
| SCHEMBL2681173 | 0.79 | GRK5 (0.58) | MAP4K3GRK2GRK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009024825-A1 | 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | disclosed |